Premium
Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer
Author(s) -
Leman Eddy S.,
Arlotti Julie A.,
Dhir Rajiv,
Greenberg Norman,
Getzenberg Robert H.
Publication year - 2002
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.10216
Subject(s) - tramp , prostate , prostate cancer , hyperplasia , adenocarcinoma , genetically modified mouse , cancer , urology , medicine , cancer research , transgene , chemistry , gene , biochemistry
The nuclear matrix (NM) contains a number of proteins that have been found to be associated with transformation. We have previously identified changes in the NM associated with prostate cancer. In this study, we examine the molecular changes that are associated with prostate cancer development in transgenic adenocarcinoma of mouse prostate (TRAMP) model by studying the differences in the NM proteins (NMPs). We collected prostates from the TRAMP males at six critical time points: 6 weeks (puberty), 11 and 19 weeks (development of mild hyperplasia), 25 weeks (development of severe hyperplasia), 31 and 37 weeks (development of neoplasia). The nuclear matrices from the prostates collected at these time points were then isolated and the NMPs were characterized by high‐resolution two‐dimensional gel electrophoresis. We found three NMPs (E1A, E1B, and E1C) that were present in the 6‐week‐old prostate and two NMPs (E2A and E2B) that were present in the 11‐week‐old prostate. These NMPs were absent in the 31‐ and 37‐week‐old prostate. We also found five NMPs (E3A–E3E) that were present in the 31‐week‐old prostate, but absent in the earlier time points. In addition, three NMPs (Le1, Le2, Le3) were present at higher expression in the 6‐, 11‐, 19‐, and 25‐weeks old TRAMP prostates, but they were expressed lower during the development of neoplasia at 31‐ and 37‐weeks old. Identification of these NMPs permits the development of novel markers that can characterize various stages of prostate cancer development as well as potentially therapeutic targets. J. Cell. Biochem. 86: 203–212, 2002. © 2002 Wiley‐Liss, Inc.